SIETES :: 93212 citas

Resultados de la búsqueda por VÍA DE ADMINISTRACIÓN REFINAR BÚSQUEDA

21.

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

22.

Anónimo. Drugs for menopausal symptoms. Med Lett Drugs Ther 2016;58:142-5. [Ref.ID 100946]

23.

Anónimo. Genmab, J&J post data allowing for faster dosing of daratumumab. DIA Daily 2016:5. [Ref.ID 100880]

24.

Anónimo. NICE reverses decision, recommends apremilast. DIA Daily 2016:2. [Ref.ID 100805]

25.

Dunlap B, Cifu AS. Clinical management of opioid use disorder. JAMA 2016;316:338-9. [Ref.ID 100637]

26.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, for the PRO-814 Study Group. Effect of buprenorphine implant on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 2016;316:282-90. [Ref.ID 100636]

27.

Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]

28.

Hawkes N. UK stands by nasal flu vaccine for children as US doctors are told to stop using it. BMJ 2016;353:i3546. [Ref.ID 100450]

29.

Levin PE. Utilizing health-care resources wisely: understanding the efficacy of our interventions: commentary on an article by Nattapol Tammachote, MD, MSc, et al.: "Intra-articular, single-shot hylan G-F 20 hyaluronic acid injection compared with corticosteroid in knee osteoarthritis. A double-blind, randomized controlled trial". J Bone Joint Surg Am 2016;98:e47. [Ref.ID 100391]

30.

Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]

31.

DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]

32.

Anónimo. FDA approves first buprenorphine implant for treatment of opioid dependence. U.S. Food and Drug Administration 2016:26 de mayo. [Ref.ID 100323]

33.

Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the Era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? meta-analysis of the published literature.. Br J Clin Pharmacol 2015:18 de diciembre. [Ref.ID 99821]

34.

Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]

35.

Baten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373:2534-48. [Ref.ID 99800]

36.

Dyer O. Canada is to legalise recreational marijuana . BMJ 2015;351:h6758. [Ref.ID 99753]

37.

Wang C, Graham DJ, Kane RC, Xie D, Wemecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu T-C, Limb S, Worrall C, Kelman JA, Reichman ME. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-8. [Ref.ID 99687]

38.

Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24. [Ref.ID 99658]

39.

Anónimo. Green tea extract for external anogenital warts. Drug Ther Bull 2015;53:114-6. [Ref.ID 99603]

40.

Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, COPOUSEP investigators West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015;386:974-81. [Ref.ID 99529]